Akorn, Inc. (AMEX: AKN) today announced the positive results of a Phase III pivotal trial for Akten๏ฟฝ. The clinical trial was a randomized, placebo controlled, multi-centered, 4-arm trial in 209 subjects. The primary efficacy end point for achieving ocular anesthesia (p
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
๊ณผ๊ฑฐ ๋ฐ์ดํ„ฐ ์ฃผ์‹ ์ฐจํŠธ
๋ถ€ํ„ฐ 9์›”(9) 2024 ์œผ๋กœ 10์›”(10) 2024 Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product ์ฐจํŠธ๋ฅผ ๋” ๋ณด๋ ค๋ฉด ์—ฌ๊ธฐ๋ฅผ ํด๋ฆญ.
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
๊ณผ๊ฑฐ ๋ฐ์ดํ„ฐ ์ฃผ์‹ ์ฐจํŠธ
๋ถ€ํ„ฐ 10์›”(10) 2023 ์œผ๋กœ 10์›”(10) 2024 Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product ์ฐจํŠธ๋ฅผ ๋” ๋ณด๋ ค๋ฉด ์—ฌ๊ธฐ๋ฅผ ํด๋ฆญ.